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MTOR associated protein, eak-7 homolog (mEAK-7), activates mechanistic target of rapamycin
(mTOR) signaling in human cells through an alternative mTOR complex to regulate S6K2 and 4E-
BP1. However, the role of mEAK-7 in human cancer has not yet been identified. We demonstrate
that mEAK-7 and mTOR signaling are strongly elevated in tumor and metastatic lymph nodes of pa-
tients with non-small-cell lung carcinoma compared with those of patients with normal lung or lymph
tissue. Cancer stem cells, CD44+/CD90+ cells, yield elevated mEAK-7 and activated mTOR signaling.
mEAK-7 is required for clonogenic potential and spheroid formation. mEAK-7 associates with DNA-
dependent protein kinase catalytic subunit isoform 1 (DNA-PKcs), and this interaction is increased
in response to X-ray irradiation to regulate S6K2 signaling. DNA-PKcs pharmacologic inhibition or ge-
netic knockout reduced S6K2, mEAK-7, and mTOR binding with DNA-PKcs, resulting in loss of S6K2
activity and mTOR signaling. Therefore, mEAK-7 forms an alternative mTOR complex with DNA-
PKcs to regulate S6K2 in human cancer cells.
INTRODUCTION
Aberrant mechanistic target of rapamycin (mTOR) signaling has been observed in many types of human
cancer (Saxton and Sabatini, 2017). Recently, mEAK-7 (mammalian EAK-7 or MTOR associated protein,
eak-7 homolog) was identified as a molecular activator of mTOR signaling in human cells (Nguyen et al.,
2018). Interestingly, mEAK-7 exhibits a preferential expression pattern in human cancer cell lines (Nguyen
et al., 2018). Although EAK-7 regulates dauer formation and lifespan in C. elegans (Alam et al., 2010), the
extent to which EAK-7 functions similarly in nematodes and mammals to regulate TOR/mTOR function is
unknown.
mEAK-7 uses the S6K2/4E-BP1 axis to regulate mTOR signaling (Nguyen et al., 2018). S6K2 signaling has
not been adequately delineated from that of S6K1 signaling owing to their assumed functional redun-
dancies (Pardo and Seckl, 2013). However, in breast cancer cells, loss-of-function studies demonstrate
that S6K1 and S6K2 have several different protein targets (Karlsson et al., 2015). In addition, canonical
models of mTOR complex 1 (mTORC1), the traditional S6K regulators, and mTORC2 may not exist similarly
in all cell types. As examples of this phenomena, an mTOR complex that involves GIT1, which is distinct
from mTORC1 and mTORC2, has been identified in astrocytes (Smithson and Gutmann, 2016), and ETS
Variant 7 is capable of binding to mTOR and sustaining mTOR signaling in the presence of rapamycin (Har-
wood et al., 2018). These pivotal findings disrupt conventional ideas regarding the existence of only two
mTOR complexes and therefore suggest the possibility of other, unidentified mTOR complexes.
Although it is largely believed that mTOR signaling is suppressed under genotoxic stress via AMPK regu-
lation of TSC2 (Feng et al., 2007), studies have demonstrated aberrant activation of mTOR signaling in
response to DNA damage. For example, mTORC1 signaling inhibits DNA damage response mechanisms
in vitro and in vivo through RNF168 (Xie et al., 2018). S6K2, another crucial mTOR target, may also function
in the DNA damage response, as S6K2 knockdown results in strong reduction of mTOR signaling, even in
the presence of DNA damage (Xie et al., 2018). Furthermore, CHK1 function relies on mTORC1 signaling in
response to DNA damage repair processes. These findings suggest that mTOR signaling supports DNA
damage responses (Zhou et al., 2017). In examining the role of radiation in DNA damage, sustained radi-
ation treatment to mice activates mTOR signaling and oxidative stress in the intestine (Datta et al., 2014),
whereas normal tissues undergoing long-term radiation stress exhibit activated mTOR signaling in mini
pigs (Zhu et al., 2016). Thus, there is a rationale to treat patients with a combination of chemotherapeutics
that induce DNA damage and mTOR inhibitors, like rapamycin, due to additive cytotoxic effects in breast190 iScience 17, 190–207, July 26, 2019 ª 2019 The Authors.
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carcinoma cell lines (Mondesire et al., 2004). These studies suggest that mTOR signaling and DNA damage
repair processes may function synergistically in specific biologic contexts, such as during the downregula-
tion of p53 via S6K-mediated activation of MDM2 (Lai et al., 2010), or the phosphorylation of 4E-BP1 phos-
phorylation in response to DNA damage (Braunstein et al., 2009). Thus, we posit a mechanism supporting
sustained mTOR signaling after genotoxic stress, which may allow enhanced cancer cell survival through
radiation resistance.
Cancer stem cells (CSCs) are known to be radiation resistant and thrive under genotoxic stress, but the
molecular mechanisms responsible for these adaptations remain unknown (Bao et al., 2006; Diehn et al.,
2009). CSCs are a self-renewing population of cells within a tumor mass (Al-Hajj et al., 2003), and mTOR
signaling has been implicated in regulating pancreatic CSC viability and self-renewal (Matsubara et al.,
2013). This suggests that this population of cancer cells utilizes mTOR signaling to contribute to the survival
and pathogenicity of human cancers. Data from a medulloblastoma in vivo model of CSCs suggest that
phosphatidylinositol 3-kinase (PI3K) signaling is activated in response to DNA damage, as indicated by
S6 regulation, a crucial readout of mTOR signaling (Hambardzumyan et al., 2008). This substantive evi-
dence suggests that mTOR signaling plays an important role in CSC DNA damage response and self-
renewal.
Given that genotoxic stressors are capable of activating mTOR signaling, select CSCs were found to
demonstrate radiation resistance, and because CSCs require mTOR signaling, we sought to determine
the extent to which mEAK-7 contributes to radiation resistance and self-renewal in cancer cells through
an alternative pathway involving mTOR.RESULTS
mEAK-7 Protein Levels Are Elevated in Metastatic Human Non-Small Cell Lung Carcinoma
Lymph Nodes
Although mEAK-7 protein levels appear to be disproportionately high in human cancer cell lines when
compared with non-cancerous cells (Nguyen et al., 2018), this limited observation does not exclude the
possibility that mEAK-7 is present in healthy human tissues, because mTOR expression is found in many
tissue types (Kim et al., 2002). To gain a better understanding of the expression pattern of mEAK-7 in
healthy human tissues, we accessed the GTEx database and identified basal-level expression of MEAK7
in many human tissues (Figure 1A). The BioGPS database also confirmed that MEAK7 is expressed in
diverse tissue types (Figure S1A) (Wu et al., 2009, 2013, 2016). Thus, future analyses of mEAK-7 in healthy
tissues are essential to understanding the role of mEAK-7 in mammalian development and metabolism.
To identify MEAK7 genomic alterations in human patients with cancer, we accessed the cBioPortal data-
base. Genetic modifications to MEAK7 included deletions, copy number amplifications, and mutations;
yet these modifications were found to be cancer type dependent (Figures 1B and 1C). For example,
many prostate cancers exhibit MEAK7 deletions, whereas breast cancers often sustain substantial
MEAK7 gene copy number amplification (Figure 1B). Because of these different genetic profiles, the search
parameters were narrowed to include only gain of expression and copy number amplification. The percent-
age of patients that demonstrated either of these anomalies ranged between 5% and 50% (Figure 1C)
(Cerami et al., 2012; Gao et al., 2013), demonstrating that MEAK7 genetic modifications are cancer type
specific and can be observed in a diverse array of human cancers.
The TCGA cBioPortal revealed high expression of MEAK7 in patients with non-small-cell lung carcinoma
(NSCLC) (Figure 1C). In addition, the majority of our first report into the mechanistic function of mEAK-7
was done in NSCLC lines, H1299 and H1975 (Nguyen et al., 2018). Therefore, the Oncomine database
was accessed to analyze MEAK7 expression patterns in lung carcinomas when compared with expression
patterns in healthy lung tissue. Through two different lung cancer studies, MEAK7 was found to be highly
expressed in many NSCLCs and small cell lung carcinomas, when compared with normal lung tissue, sug-
gesting thatMEAK7may play a role in lung tumorigenesis (Figures 1D and 1E) (Rhodes et al., 2004). Also, an
association was found between MEAK7 expression and outcomes of patients with cancer. Patients who
died from ductal breast carcinoma (p = 2.72 3 106, Fold Change: 2.136) and acute myeloid leukemia
(p = 7.99 3 105, Fold Change: 2.655) had enhanced MEAK7 expression (Figures S1B and S1C) (Rhodes
et al., 2004). Thus theMEAK7 expression profile of patients with cancer may provide insight into predicting
patient prognosis and survival.iScience 17, 190–207, July 26, 2019 191
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Figure 1. MEAK7 Gene Expression Is Detected in Normal Human Cells and Upregulated in Select Human Cancer Types
(A) Genotype-Tissue Expression (GTEx) database analysis of MEAK7 expression in normal human tissues.
(B and C) (B) The Cancer Genome Atlas cBioPortal analysis MEAK7 for all genomic alterations or (C) for only gain of mRNA expression or amplification of
gene copy number. The results shown are based on data generated by TCGA Research Network: http://cancergenome.nih.gov/.
(D and E) Oncomine analysis of MEAK7 gene expression of patients with normal lung and lung cancer via two different studies: (D) Garber Lung Study
analysis by Student’s t test 2-sample equal variance and (E) Hou Lung Study analysis by Mann-Whitney U test, p < 0.01, 2-tailed.In a screen of human squamous cell carcinomas, the UM-SCC-17A cell line (Brenner et al., 2010), derived
from the primary laryngeal cancer site of a 48-year-old female patient, did not express detectable levels
of mEAK-7 protein (Nguyen et al., 2018). Interestingly, the UM-SCC-17B cell line, derived from a metastatic
site from the same patient, did express mEAK-7 (Nguyen et al., 2018). These findings suggest that
increased expression of mEAK-7 may be associated with tumor metastasis. To test the hypothesis that
elevated mEAK-7 protein levels are associated with cancer metastasis, the protein expression patterns
of primary tumors and confirmed metastasizes closest to lymph tissues of patients with cancer were
compared with healthy lung and lymph tissues. An NSCLC tissue microarray containing 30 individual
pathologist-graded, patient-matched sections of primary tumors, as well as their normal adjacent tissue,
and metastatic lymph nodes were stained and analyzed. mEAK-7 and (Ser240/244) p-S6 protein levels
were significantly elevated in the primary human tumor when compared with the normal adjacent tissue
(Figures 2A–2C). Furthermore, mEAK-7 and (Ser240/244) p-S6 protein levels were significantly greater in
the metastatic lymph nodes when compared with both primary tumor and normal adjacent tissue (Figures
2A–2C). However, healthy adult lymph tissue did not yield substantial mEAK-7 or (Ser240/244) p-S6 protein
levels (Figure S2A). Thus, mEAK-7 protein and activated mTOR signaling was found to be enhanced in pri-
mary NSCLC, and substantially detected in metastasized lymph nodes, suggesting that mEAK-7 could
function as a biomarker for patients with metastasized cancers.
As Oncomine databases demonstrate that higherMEAK7 expression is associated with poor patient prog-
noses (Figures S1B and S1C), we sought to investigate this via a lung adenocarcinoma tissue microarray
detailing patient survival data. The microarray stained with antibodies targeting endogenous mEAK-7
and (Ser240/244) p-S6 and a Kaplan-Meier Survival Curve analysis illustrated that mEAK-7 protein levels
were strongly associated with poor patient prognosis, specifically in patients with relapse following surgical
intervention (Figure 2D).
Because mEAK-7 protein levels were highly expressed in metastasized lymph nodes, we tested the extent
to which mEAK-7 is required for cell invasion in vitro. To test this, H1975 cells were treated with control or
mEAK-7 small interfering RNA (siRNA) for 48 h and 50,000 cells were seeded into invasion chambers for
24 h. Results demonstrated a statistically significant reduction in cell invasion after 24 h (Figure 2E).
Thus, mEAK-7 may be a clinically relevant biomarker for predicting the prognosis of patients with metasta-
tic NSCLC.Cancer Stem Cells Exhibit High Protein Levels of mEAK-7 and mTOR Signaling
mEAK-7 is a strong, positive regulator of mTOR signaling (Nguyen et al., 2018), and several groups
have demonstrated that mTOR signaling is essential for CSC self-renewal (Matsubara et al., 2013)
and radiation resistance (Fang et al., 2013). Therefore, we hypothesized that mEAK-7 is differentially ex-
pressed in the CSC versus non-CSC populations. Because the majority of information on human mEAK-7
has been demonstrated in NSCLC cell lines H1975 and H1299, we sought to determine the expression
profile of mEAK-7 and mTOR signaling in NSCLC CSCs. These cells are best identified as being
CD44+ (Leung et al., 2010) and CD90+ (Wang et al., 2013). Therefore, H1299 cells were subjected to
fluorescence-activated cell sorting for the aforementioned markers. CD44+/CD90+ cells, representing
1% of all cells sorted, were analyzed for mEAK-7 and mTOR signaling (Figure 3A). Immunoblot analysis
demonstrated that CD44+/CD90+ H1299 cells, when compared CD44/CD90, yielded greater
protein levels of mEAK-7 and S6K2, as well as activated mTOR signaling, as measured via p-S6 and
p-4E-BP1 protein levels (Figure 3B). The CD44+/CD90+ cell population expressed n-cadherin (Fig-
ure 3B), which is known as an essential component of the epithelial-mesenchymal transition state
in CSCs and suggests that high levels of mEAK-7 in cancer cells are more likely to metastasize (Liu
et al., 2014). Similar results were observed in CD44+/CD90+ H1975 cells (Figures S2B and S2C). Collec-
tively, these results demonstrate that there is a selective expression profile of mEAK-7 and S6K2 in self-
renewing CSCs.iScience 17, 190–207, July 26, 2019 193
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Figure 2. mEAK-7 Protein Levels Are High in Nearby Lymph Nodes of the Tumor Mass in Patients with NSCLC
(A) Three representative human patient tissue sections stained for (Ser240/244) p-S6 and mEAK-7. Scale bar, 250 mm.
(B) Statistical analysis of 30 paired patients with NSCLC with the normal lung, primary tumor, and metastasized lymph node for (Ser240/244) p-S6 staining.
Mann-Whitney U test was used.
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Figure 2. Continued
(C) Statistical analysis of 30 paired patients with NSCLC with the normal lung, primary tumor, and metastasized lymph node for mEAK-7 staining. Mann-
Whitney U test was used.
(D) NSCLC tissue microarray analysis of Kaplan-Meier survival curves. Log rank test was used.
(E) H1975 cells were treated with control or mEAK-7 siRNA for 48 h; 50,000 cells were seeded into in vitroMatrigel-based invasion chambers and allowed to
grow for 24 h. Analyzed by Student’s t test (n = 6). ***p < 0.0001. Experiments were repeated at least six times.mEAK-7 Is Necessary for Clonogenic Potential and Spheroid Formation in Human Cancer
Cells
To test the hypothesis that mEAK-7 affects cell survival following X-ray irradiation damage, a 2D clonoge-
nicity assay was used to assess the surviving fraction of irradiated cancer cells (Franken et al., 2006; Puck and
Marcus, 1956). H1299 and H1975 cells were treated with control or mEAK-7 siRNA for 48 h and then sub-
jected to no treatment or X-ray irradiation of 2 or 6 Gy. These cells were then reseeded into new 60-mm
tissue culture plates and allowed to grow for 10 days. In both H1299 and H1975 cells, clonogenic potential
was significantly decreased after mEAK-7 knockdown, but little additional effects were found after expo-
sure to 2- and 6-Gy X-ray irradiation in both H1299 and H1975 cells (Figures 3C–3H). This suggests that
mEAK-7 alone is capable of regulating clonogenic potential to a dramatic extent. In H1299 and H1975 cells,
similar results were observed at higher cell seeding densities (Figure S2D) or by utilizing a different siRNA
mEAK-7 (Figures S3A and S3B), demonstrating that mEAK-7 enhances the clonogenic potential of human
cancer cells in response to DNA damage.
Two-dimensional assays measuring clonogenic potential demonstrate the essential role of mEAK-7 in the
DNA damage response, whereas 3D assays better simulate in vivo conditions. The spheroid-forming assay
is a widely accepted experimental strategy to identify stem cell self-renewal in mammalian cell systems
in vitro and in vivo (Pastrana et al., 2011). Furthermore, CSCs are the principal cancer cell population
responsible for spheroid formation (Weiswald et al., 2015). Thus, to test the effect of mEAK-7 on spheroid
size and formation, H1975 cells were treated with control or mEAK-7 siRNA for 48 h, subjected to no treat-
ment or 2- or 6-Gy X-ray irradiation, and subsequently seeded in ultra-low attachment dishes for 1 week.
mEAK-7 knockdown resulted in a dramatic reduction in spheroid size with no treatment, or 2- or 6-Gy treat-
ment (Figure 4A). In addition, the gross number of spheroids formed was significantly reduced after
mEAK-7 knockdown, and even further reduced following 2- or 6-Gy X-ray irradiation treatment (Figure 4B).
Similar results were observed when H1975 cells were seeded at a lower density (Figure S3C) and when a
different mEAK-7 siRNA was used in both H1299 and H1975 cells (Figures S3D and S3E). These results
collectively indicate that mEAK-7 plays a significant role in cancer cell spheroid formation.
mEAK-7 Is Necessary for Chemoresistance, Radiation Resistance, and Sustained DNA
Damage-Mediated mTOR Signaling in Human Cancer Cells
Although X-ray irradiation is a potent inducer of the DNA damage response pathway, we hypothesized that
other forms of genotoxic stress may similarly regulate mEAK-7. Cisplatin is a chemotherapeutic drug often
used to treat patients with cancer with solid tumors. Cisplatin is widely used for the treatment of solid tu-
mors because it has the ability to activate the DNA damage response and allow cells to undergo apoptosis.
Although the mechanism of action would take 20 years to unravel, it was clear that cisplatin produced DNA
adducts and forced double-stranded breaks in the DNA. However, following initial tumor regression, a
fraction of solid tumors become chemoresistant (Galluzzi et al., 2012). mTOR signaling can be activated
during cisplatin treatment of ovarian cancer cells over time, as measured by enhanced (Thr389) p-S6K1 pro-
tein levels (Peng et al., 2010). As mEAK-7 is required for mTOR signaling, we tested the hypothesis that
mEAK-7 is an essential modulator of mTOR signaling following genotoxic stress induced by cisplatin treat-
ment. To test the extent to which genotoxic stress modifies mEAK-7 activity, H1299 cells were treated
with mEAK-7 siRNA for 48 h. Next, these cells were treated with either DMSO or 10 mM cisplatin for 4 or
8 h. mEAK-7 protein levels were increased in response to DNA damage by cisplatin treatment. Further-
more, mEAK-7 was required for regulation of (Ser65) p-4E-BP1, an indicator of mTOR signaling (Figure 4C).
Therefore, cisplatin is capable of regulating mEAK-7-mediated mTOR signaling.
mEAK-7 Knockdown Impairs the DNA Damage Response and Enhances Noxa Levels after
X-Ray Irradiation
Cancer cells utilize many mechanisms to promote radioresistance in response to cancer therapies (Kim
et al., 2009). To determine the role of X-ray irradiation on mEAK-7 and the DNA damage response,iScience 17, 190–207, July 26, 2019 195
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Figure 3. mEAK-7 Is Expressed in CD44+/CD90+ Group and Required for Clonogenic Potential and Radiation Resistance
(A) Flow sort diagram depicting the CD44+/CD90+ cell population in H1299 cells.
(B) Immunoblot analysis of CD44/CD90 and CD44+/CD90+ H1299 cells for mEAK-7 and mTOR signaling.
(C) H1299 cells were treated with control or mEAK-7 siRNA for 48 h, X-ray irradiated at 2 or 6 Gy, and 2,500 cells were seeded into 60-mm tissue culture plates
(TCPs) and grown for 10 days.
(D) H1975 cells were treated with control or mEAK-7 siRNA for 48 h and subjected to no treatment or 2- and 6-Gy X-ray irradiation, and 5,000 cells were
seeded into 60-mm TCPs and grown for 10 days. Scale bars, 2.5 mm.
(E) H1299 surviving fraction analysis for (C).
(F) H1975 surviving fraction analysis for (D).
(G) H1299 colony number graphs for (C).
(H) H1975 colony number graphs for (D).
Analysis of clonogenic assay via Student’s t test. **p < 0.001, ***p < 0.0001, xp < 0.000001. All experiments were repeated at least three times, and (C–H) was
repeated six times.H1975 cells were treated with control or mEAK-7 siRNA, and X-ray irradiated with 20 Gy for up to 2 h. H1975
cells treated with mEAK-7 siRNA exhibited a dramatic increase in Noxa levels (Figure 4D). We also found
similar results in H1299 cells treated with mEAK-7 siRNA and subjected to X-ray irradiation (Figure S3F).
Upregulation of Noxa occurs in response to DNA damage after mEAK-7 knockdown (Figure 4D), which
ultimately leads to cellular apoptosis (Ploner et al., 2008), suggesting that mEAK-7 plays a role in the
DNA damage response and cancer cell survival. Noxa is known to be regulated by p53-dependent mech-
anisms through oncogene-independent apoptosis induced by genotoxic stressors, where p53 activates
both survival and apoptotic pathways through p21WAF1/Cip1 (Shibue et al., 2003). However, Noxa has
also been shown to function through p53-independent mechanisms, where ATF3 and ATF4 are induced
by cisplatin, a DNA-damaging agent, and downregulation of ATF3 or ATF4 reduces Noxa expression
because ATF3 and ATF4 bind to and cooperatively activate the Noxa promoter (Sharma et al., 2018). As
H1975 is a p53 wild-type NSCLC line and H1299 is a p53-null NSCLC line, mEAK-7 may regulate Noxa
expression through a p53-independent mechanism.
The comet assay is used to quantify intracellular DNA damage resulting from an insufficient DNA damage
repair response in eukaryotic cells (Collins, 2004). H1299 and H1975 cells were independently embedded in
an agarose gel and lysed, thereby releasing intracellular DNA. During gel electrophoresis, DNA fragments
migrate toward the anode, resulting in a ‘‘comet’’ pattern with a trail of DNA fragments, such that a longer
trail signifies more fragments, and therefore more DNA damage (Ostling and Johanson, 1984). Owing to
the dramatic results from radiation treatment withmEAK-7 knockdown in the clonogenicity (Figures 3C–3H)
and spheroid assays (Figures 4A and 4B), we hypothesized that mEAK-7 plays a crucial role in the DNAdam-
age repair pathways. The visualization of DNA strandmigration via the comet assay, and subsequent quan-
tification of that migration, allowed us to predict the relative levels of the DNA repair response. H1299 and
H1975 cells were treated with control or mEAK-7 siRNA and subjected to no treatment or 2- or 6-Gy X-ray
irradiation for 30 min. Comet pattern formations, quantified as tail DNA %, were enhanced in H1299 and
H1975 cells treated with mEAK-7 siRNA and X-ray irradiation (Figures 4E–4H), suggestingmEAK-7 is neces-
sary for the DNA repair response in these cancer cells.mEAK-7 Interacts with DNA-PKcs in Response to X-Ray Irradiation Damage
To determine the extent to which mEAK-7 regulates genotoxic activation of mTOR signaling, we sought to
identify interacting partners of mEAK-7 by transducing H1299 cells with a lentivirus expressing pLenti-GIII-
HA(c-term)mEAK-7. Through hemagglutinin (HA)-mEAK-7 immunoprecipitation (IP) and mass spectro-
metric (MS) analysis, a list of proteins that potentially interact with mEAK-7 was generated (Table S1).
DNA-dependent protein kinase catalytic subunit isoform 1 (DNA-PKcs) scored the highest with 241 exclu-
sive spectral counts and 36% protein coverage (Figure 5A). As with the canonical role of DNA-PKcs in the
DNA damage response, ataxia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) also play
essential and redundant roles in repairing damaged DNA, because all three share similar targets in
response to DNA damage (Ciccia and Elledge, 2010; Nguyen et al., 2018). These data suggest that other
phosphatidylinositol 3-kinase-related kinase (PIKK) members, like DNA-PKcs andmTOR, could also work in
concert to regulate metabolism. Thus, we posited that mEAK-7 regulates mTOR signaling, in part, through
the interaction with DNA-PKcs.
To confirm our IP/MS results, protein lysates were harvested from H1299 cells stably transduced with HA-
mEAK-7. Exogenous mEAK-7 interacted with endogenous DNA-PKcs (Figures 5B and 5C). Under UV BiScience 17, 190–207, July 26, 2019 197
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Figure 4. mEAK-7 Is Required for Spheroid Formation and Is Necessary for an Effective DNA Damage Response
(A) Images of spheroids. H1975 cells were treated with control or mEAK-7 siRNA, X-ray irradiated at 2 or 6 Gy, and 10,000
cells were seeded into 60-mm ultra-low attachment plates and grown for 10 days. Scale bar, 125 mm.
(B) Quantification of spheroid formation and analysis via Student’s t test (n = 6) of (A). *p < 0.01, **p < 0.001.
(C) H1299 cells were treated with control or mEAK-7 siRNA and with DMSO or 10 mM cisplatin for 4 or 8 h, and mTOR
signaling was analyzed.
(D) H1975 cells were treated with control or mEAK-7 siRNA and X-ray irradiated at 20 Gy for 30 min, 1 h, or 2 h and analyzed
for Noxa expression by DNA damage response.
(E and F) H1299 and H1975 cells were treated with control or mEAK-7 siRNA and X-ray irradiated at 2 or 6 Gy for 30 min and
assessed via the comet assay to detect damaged DNA. Scale bar, 250 mm.
(G and H) Statistical analysis via Student’s t test (n = 15) of (E and F) represented as box plots. *p < 0.01, **p < 0.001,
zp < 0.00001, xp < 0.000001, Up<0.0000001. All experiments were repeated at least three times.irradiation, DNA-PKcs has been shown to interact with mTOR kinase and SIN1 to affect mTORC2 signaling
in epithelial skin keratinocytes, but the molecular rationale for this interaction remains elusive (Tu et al.,
2013). Furthermore, nuclear DNA-PKcs transverses to the cytosol in response to DNA damage (Tu et al.,
2013). This ability to travel to the cytoplasm, combined with evidence that DNA-PKcs can activate meta-
bolism-related genes, suggests a role for DNA-PKcs in metabolic signaling.
Because mEAK-7 interacts with mTOR in increasing amounts of amino acid, insulin, or nutrient conditions
(Nguyen et al., 2018), we sought to determine the extent to which mEAK-7 increases its binding to
DNA-PKcs after DNA damage. H1299 cells stably expressing HA-mEAK-7 were subjected to no treatment
or X-ray irradiated with 10 Gy for 30 or 60 min, and results revealed that mEAK-7 increasingly interacted
with DNA-PKcs over time in response to DNA damage (Figure 5D). These data suggest that mEAK-7 asso-
ciates with DNA-PKcs and mTOR to form a third mTOR complex (mTORC3), distinct from mTORC1 and
mTORC2.
First, to determine the extent to which S6K2 is required for mTOR signaling following X-ray irradiation,
H1975 and H1299 cells were treated with controls or two unique S6K1 or S6K2 siRNAs. Results revealed
that p-S6 levels were abrogated after S6K2 knockdown in H1975 and H1299 cells (Figures S4A and S4B),
suggesting that S6K2 is necessary for sustained S6 phosphorylation in response to DNA damage. S6K2
is capable of binding to mTOR in the presence of nutrient stimulation (Nguyen et al., 2018), but it is un-
known whether S6K2 binds to DNA-PKcs. As mEAK-7 is required for the mTOR-S6K2 axis (Nguyen et al.,
2018), DNA-PKcs and S6K2 binding was tested to determine the extent to which mEAK-7 and DNA-PKcs
form a complex that regulates mTOR signaling through S6K2. To test whether S6K2 interacts with DNA-
PKcs in the presence of DNA damage, H1299 cells were transiently transfected with pcDNA3-HA-S6K2-
WT; subsequently, they were X-ray irradiated with 10 Gy for 1 h and HA-S6K2 was immunoprecipitated.
X-ray irradiation considerably increased the interaction between DNA-PKcs and HA-S6K2, whereas it
had little to no influence on mTOR and HA-S6K2 interaction (Figure 5E). Conversely, HA-S6K1 binding
to DNA-PKcs was observed, but there was a severe reduction in binding after DNA damage, suggesting
that S6K1 is not the main downstream target of DNA-PKcs after DNA damage (Figure S4C). These findings
were reproduced under nutrient stimulation as well, where DNA-PKcs enhances binding to HA-S6K2 and
DNA-PKcs diminishes binding to HA-S6K1 (Figure S4D). DNA-PKcs is capable of interacting with S6K2
to regulate its function in response to DNA damage. To determine if mTOR is required for mEAK-7-medi-
ated DNA-PKcs function and interaction, mTOR was knocked down with two different mTOR siRNAs, which
resulted in a dramatic reduction of DNA-PKcs interaction with endogenous mEAK-7 (Figure 5F). This col-
lective evidence links mEAK-7 to the major metabolic sensor, mTOR, and the crucial DNA damage repair
regulator, DNA-PKcs.
Although we previously established the function of mEAK-7 in mTOR signaling under nutrient conditions
(Nguyen et al., 2018), its role in mTOR signaling under genotoxic stressors remains unknown. To test the
hypothesis that mEAK-7 is required for mTOR activation after DNA damage, H1299 and H1975 cells
were treated with control or mEAK-7 siRNA for 48 h in DMEM with 10% fetal bovine serum (FBS). Two
different conditions were compared: 1-h nutrient starvation with 30-min nutrient replenishment was
compared with 10-Gy X-irradiation for 30 min. Under these conditions, mEAK-7 was also capable of regu-
lating sustained activation of mTOR signaling after X-ray irradiation in NSCLC (Figure 5G). Thus, mEAK-7 is
capable of regulating nutrient-dependent mTOR signaling, as well as X-ray irradiated activation of mTOR
signaling.iScience 17, 190–207, July 26, 2019 199
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Figure 5. mEAK-7 Forms a Third mTOR Complex with DNA-PKcs to Regulate S6K2 Activity
(A) H1299 cells stably expressing HA-mEAK-7 were lysed in 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS) buffer, HA-mEAK-7 was
immunoprecipitated, and co-immunoprecipitated proteins were analyzed for mass spectrometry quantitative profiling.
(B) H1299 cells stably expressing HA-mEAK-7 were lysed in NP40 lysis buffer and using IgG control antibody or HA-tag antibody, HA-mEAK-7 was
immunoprecipitated to check DNA-PKcs interaction.
(C) Non-transduced H1299 cells or H1299 cells stably expressing HA-mEAK-7 were lysed in CHAPS lysis buffer, and HA-tag antibody was used for
immunoprecipitation to check DNA-PKcs or mTOR interaction.
(D) H1299 cells stably expressing HA-mEAK-7 were untreated or X-ray irradiated at 10 Gy for 30 min and 1 h and lysed in NP40 lysis buffer. HA-mEAK-7 was
immunoprecipitated to check DNA-PKcs interaction.
(E) H1299 cells were transiently transfected with pcDNA3-HA-S6K2 and then untreated or X-ray irradiated at 10 Gy for 1 h. HA-S6K2 was immunoprecipitated
to check DNA-PKcs or mTOR interaction.
(F) H1975 cells were transiently transfected with control or mTOR #1 or mTOR #2 siRNA for 48 h. Cells were collected in CHAPS, and endogenous mEAK-7
was immunoprecipitated to check DNA-PKcs interaction.
(G) H1299 and H1975 cells were transiently transfected with control or mEAK-7 siRNA for 48 h. Cells were subsequently starved of nutrients for 1 h and
replenished with DMEM+AAs and 10 mM insulin for 30 min or cultured normally and treated with 10-Gy X-ray irradiation for 30 min. Immunoblot analysis was
conducted for mTOR signaling proteins.
(H) H1975, H1299, and HEK293T cells were transfected with no plasmid, pRK7-HA-S6K1-WT, and pcDNA3-HA-S6K2. HA-tag antibody was
immunoprecipitated and probed for DNA-PKcs, mTOR, and Raptor.
(I) H1299 and H1975 cells were treated with either DMSO or NU7441 (DNA-PKcs inhibitor) at 5 mM for 2 h and mixed in fresh DMEM with 10% FBS. Cells were
collected in CHAPS, S6K2 was immunoprecipitated, and immunoblots were utilized to assess mTOR signaling. GAPDH was used for loading controls.
(J) DNA-PKcsWT and DNA-PKcs/ HEK293T cells were transfected with pcDNA3-HA-S6K2 or pRK7-HA-S6K1-WT. Before protein isolation, cells were fed
fresh DMEM with 10% FBS for 1 h before collection in CHAPS. HA-tag antibody was immunoprecipitated and probed for mTOR and activated S6K2
signaling.
(K) Experimental protocols were repeated from (J), and mTOR antibody was immunoprecipitated and probed for mTOR, HA-S6K2, and S6K1.
(L) DNA-PKcsWT and DNA-PKcs/ HEK-293T cells were collected in CHAPS lysis buffer. Endogenous mEAK-7 was immunoprecipitated and probed for
mTOR and DNA-PKcs. All experiments were repeated at least three times.Next, to determine the relative binding affinities of S6K1 and S6K2 to their most relevant complex, we trans-
fected H1299, H1975, and HEK-293T cells with HA-S6K1 or HA-S6K2 and immunoprecipitated HA-S6K1 or
HA-S6K2 to probe for mTOR, raptor, and DNA-PKcs binding. Interestingly, we discovered that HA-S6K1 is
capable of binding to DNA-PKcs, but HA-S6K2 binds to DNA-PKcs to a significantly larger extent (Fig-
ure 5H). Furthermore, we found that raptor binding to HA-S6K1 was strong, whereas HA-S6K2 binding
to raptor was weaker (Figure 5H). This suggests that S6K1 and S6K2 have preferential binding affinities
to mTORC1, or alternative mTOR complexes. Finally, to test the extent to which DNA-PKcs activity is
required for S6K2 function, H1299 and H1975 cells were treated with either DMSOor 5 mMNU7441, a highly
specific chemical inhibitor of DNA-PKcs, for 2 h under freshly stimulated 10% FBS medium. NU7441 is
1,0003 more specific for DNA-PKcs than PI3K and 2003 more specific for DNA-PKcs than mTOR. DNA-
PKcs inhibition resulted in a substantial decrease in S6K2/mTOR/DNA-PKcs binding, as well as S6K2 func-
tional activity (Figure 5I). These results suggest that mEAK-7 structurally links DNA-PKcs and S6K2 to mTOR
signaling.
Although pharmacologic agents are potent molecules to dissect the downstream pathways within cells,
they still may yield non-specific targeting. To rule out non-specific interactions of DNA-PKcs inhibitors
with other kinases, we obtained validated DNA-PKcs/ HEK293T cells (Neal et al., 2016). In DNA-PKcs/
cells, IP demonstrated that HA-S6K2 phosphorylation was diminished and HA-S6K2 binding to mTOR was
reduced, but HA-S6K1 phosphorylation andHA-S6K1 binding tomTORwereminimally affected (Figure 5J).
IP of mTOR in DNA-PKcs/ cells transfected with HA-S6K2 resulted in abrogated binding to HA-S6K2 and
increased binding to HA-S6K1, demonstrating that mTOR utilizes DNA-PKcs to form a new complex to
target S6K2 (Figure 5K). Finally, loss of DNA-PKcs inhibited the ability of mEAK-7 to bind to mTOR, sug-
gesting that mEAK-7, DNA-PKcs, and mTOR form a stable complex to regulate S6K2 (Figure 5L).
mEAK-7 Is Required for Sustained IR-Mediated mTOR Signaling in Human Cancer Cells and
Loss of mEAK-7 Results in Enhanced PARP Cleavage
As we determined that mEAK-7 knockdown combined with X-ray irradiation resulted in strong Noxa upre-
gulation, we posited that other markers of cell apoptosis would also be affected by mEAK-7. PARP cleav-
age has been shown to be an essential mediator of cell apoptosis and cell death (Morales et al., 2014). To
determine the extent to which mEAK-7 regulates PARP cleavage, H1299 cells treated with mEAK-7 siRNA
resulted in enhanced levels of cleaved PARP (Figure 6A). These results suggest mEAK-7 is required for ra-
diation resistance and that the loss of mEAK-7 results in severe reduction of mTOR signaling and enhanced
PARP cleavage.iScience 17, 190–207, July 26, 2019 201
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Figure 6. mEAK-7 and DNA-PKcs Are Required for X-Ray Irradiation-Mediated mTOR Signaling
(A) H1299 cells were treated with control or mEAK-7 siRNA for 48 h; X-ray irradiated at 10 Gy for 30 min, 2 h, and 8 h; and analyzed for PARP cleavage.
(B) H1975 cells were transiently transfected with control or mEAK-7 siRNA for 48 h. Next, cells were treated with 10-Gy X-ray irradiation for 30min, followed by
IP of endogenous S6K2, and probed for activated S6K2 signaling.
(C) H1299 and H1975 cells were treated with control or mEAK-7 siRNA for 48 h; X-ray irradiated at 10 Gy for 30 min, 2 h, and 8 h; and analyzed for mTOR
signaling.
(D) H1975 cells were treated with control, mEAK-7, S6K1, and S6K2 siRNA for 48 h; X-ray irradiated at 10 Gy for 30 min and 1 h; and analyzed for mTOR
signaling.
(E) H1975 cells were treated with DMSO, DNA-PKcs inhibitor (5 mM NU7441 IC50 = 14 nM), mTOR inhibitor (100 nM rapamycin, IC50 = 1 nM), and PI3K
inhibitor (50 mM LY249002, IC50 = 2.3 mM) for 1 h before being treated with X-ray irradiation at 10 Gy for 30 min and 1 h and analyzed for mTOR signaling.
(F) Working model for a mEAK-7-mTOR-DNA-PKcs complex. All experiments were repeated at least three times. GAPDH was used for loading controls.Next, we posited that mEAK-7 was required for S6K2 phosphorylation and activation after X-ray irradiation.
H1975 cells were treated with control or mEAK-7 siRNA for 48 h and 10-Gy X-ray irradiation for 30 min. IP of
endogenous S6K2 demonstrated that mEAK-7 knockdown resulted in a dramatic decrease in X-ray irradi-
ation-mediated S6K2 phosphorylation (Figure 6B). Use of a different mEAK-7 siRNA also resulted in a
decrease in S6K2 phosphorylation after DNA damage (Figure S4E). Moreover, the literature details exam-
ples of sustained mTOR signaling following DNA damage as a modulator of self-renewal and radiation
resistance (Silvera et al., 2017). To test the hypothesis that mEAK-7 is necessary for sustained X-ray irradi-
ation-mediated mTOR signaling, H1299 and H1975 cells were treated with control or mEAK-7 siRNA for
48 h in DMEM with 10% FBS and then with 10-Gy X-irradiation for 30 min, 2 h, or 8 h. H1299 and H1975 cells
treated with mEAK-7 siRNA exhibited abrogatedmTOR signaling over time (Figure 6C). These results were
also confirmed in MDA-MB-231 cells, a triple-negative breast carcinoma cell line (Figure S5). Therefore,
these results suggest that mEAK-7 is required for sustained mTOR signaling as well as cell survival after
DNA damage, and that the loss of mEAK-7 results in severe reduction of mTOR signaling and enhanced
PARP cleavage.
Both S6K1 and S6K2 are essential components of mTOR signaling that are described to have similar, but
distinct, cellular roles in human development and disease (Pardo and Seckl, 2013). To elucidate the roles of
S6K1 and S6K2 following X-ray irradiation damage, (Ser240/244) p-S6 levels were measured in response to
siRNA-mediated knockdown of mEAK-7, S6K1, or S6K2 and treatment with 10-Gy X-ray irradiation.
H1975 cells were treated with control, mEAK-7, S6K1, or S6K2 siRNA for 48 h in DMEM with 10% FBS. Sub-
sequently, the cells were treated with 10-Gy X-ray irradiation for 30 min or 1 h. mEAK-7 and S6K2 knock-
down each markedly reduced (Ser240/244) p-S6 levels, but S6K1 knockdown did not have a substantial effect
on (Ser240/244) p-S6 levels (Figure 6D). These results mirrored the nutrient conditions, as previously pub-
lished (Nguyen et al., 2018). Furthermore, mEAK-7 or S6K2 knockdown dramatically increased (Thr389)
p-S6K1 levels following X-ray irradiation-induced damage, suggesting a specific role for S6K2 and
mEAK-7 during X-ray irradiation-mediated mTOR signaling (Figure 6D).
Although some reports suggest a possible intersection of DNA-PKcs andmTOR signaling, these ideas have
not yet been fully validated across a spectrum of cell types and experimental conditions. In an effort to test
the hypothesis that DNA-PKcs and mTOR signaling depend on mEAK-7 to carry out a shared function, we
treated H1299 and H1975 cells with NU7441. NU7441 treatment significantly reduced infrared (IR)-medi-
ated mTOR signaling in a dose-dependent manner, but had little effect on (Ser2448) p-mTOR levels (Fig-
ure S6A). To determine whether NU7441 significantly inhibits IR-induced activation of mTOR signaling
compared with other mTOR inhibitors, we used specific inhibitors of DNA-PKcs (NU7441), mTOR (rapamy-
cin), and PI3K (LY249002). Inhibition of DNA-PKcs, mTOR, or PI3K significantly decreased mTOR signaling
in H1975 cells (Figure 6E). These results were also consistent in H1299 cells (Figure S6B). In conclusion,
DNA-PKcs is a fundamental component of a novel mTOR complex that regulates the mEAK-7/mTOR
signaling axis and targets S6K2.DISCUSSION
Surgical intervention and radiation therapy are common treatment modalities for patients with solid tu-
mors. However, in many patients the condition relapses as tumors acquire resistance through intratumoral
evolution (McGranahan and Swanton, 2017). CD44+/CD90+ cells have been identified as a unique popu-
lation of cancer cells that may be required for the regulation of chemo- and radioresistance through PI3K
and mTOR signaling (Chang et al., 2013). Furthermore, the literature demonstrates that S6K2 inhibits
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forms of breast cancer (Pe´rez-Tenorio et al., 2011). Similarly, a retrospective study conducted on patients
with breast cancer demonstrated that 4E-BP1 and S6K2 were correlated with poor prognosis and endocrine
resistance (Karlsson et al., 2013). This evidence, combined with our findings that mTOR signaling, mEAK-7,
and S6K2 are upregulated in CD44+/CD90+ cancer cell populations, suggests that mEAK-7 is involved in
mTOR signaling in CSCs.
Although CD44+/CD90+ cells demonstrate radiation resistance and self-renewal capacity that correlate
with elevated mEAK-7 protein levels, loss of mEAK-7 alone does not result in enhanced cell apoptosis in
human cancer cells (Nguyen et al., 2018). The combination of DNA damage and loss of mEAK-7 is capable
of enhancing cell apoptosis. This is likely because the mechanisms that support cell survival and self-
renewal are different. As PI3K and mTOR signaling are crucial regulators of radiation resistance and self-
renewal in many carcinomas, including cervical carcinoma (Kim et al., 2010), head and neck squamous
cell carcinoma (Leiker et al., 2015), and breast carcinoma (Steelman et al., 2011), it is important to note
that mEAK-7 is also a strong effector of these processes. Specifically, CSCs have been identified as a
cell population that modulates radiation resistance and self-renewal in solid tumors (Pajonk et al., 2010).
Alternative mTOR signaling appears to be upregulated in human patients with cancer, specifically in pa-
tients with metastatic disease (Figures 2A–2C). Here, DNA-PKcs was identified as a new interacting partner
of mEAK-7 (Figures 5A–5H) and may participate in the regulation of this alternative mTOR signaling. DNA-
PKcs is a member of the PIKK family that includes mTOR, ATM, ATR, suppressor of morphogenesis in geni-
talia (SMG1), and transformation/transcription domain-associated protein (TRRAP) (Lovejoy and Cortez,
2009). DNA-PKcs has been extensively studied in the context of non-homologous end joining and homol-
ogous recombination, both of which are DNA damage repair pathways (Smith and Jackson, 1999). PIKKs
typically have redundant cellular roles, depending on their cellular localization and biologic context. For
example, DNA-PKcs, ATM, and ATR all have similar cellular targets in response to DNA damage (Ciccia
and Elledge, 2010). Intriguingly, DNA-PKcs was found to play a critical role in metabolic gene regulation
in response to insulin (Wong et al., 2009). However, DNA-PKcs predominantly resides in the nucleus, so
it was initially unclear how DNA-PKcs could exit the nucleus to affect nutrient metabolism. The literature
supports the observation that pockets of DNA-PKcs exists in lipid rafts outside of the nucleus, suggesting
the existence of a different role for DNA-PKcs in cytoplasmic cellular signaling (Lucero et al., 2003). In sup-
port of these diverse findings, we demonstrate that DNA-PKcs interacts with mEAK-7 to regulate mTOR
signaling, predominantly through S6K2.
In mini pigs, mTOR signaling is enhanced in salivary glands 5 days after treatment with X-ray irradiation (Zhu
et al., 2016). In addition, PI3K and mTOR are essential regulators of radiation resistance in prostate cancer
cells (Chang et al., 2014) as dual PI3K-mTOR inhibitors re-sensitize cancer cells to radiation treatment
(Mukherjee et al., 2012). Here, we demonstrate that mEAK-7 is required for the sustained activity of
mTOR signaling following X-ray irradiation damage. Continued investigation of mEAK-7 and other molec-
ular machinery that regulates IR damage-mediated activation of mTOR signaling will allow for the creation
of targeted inhibitors promoting radiation re-sensitization.
As the role of mEAK-7 is further studied in the context of human disease, its unique role in nutrient-sensing
and DNA damage response (Figure 6F) will likely expand. S6K2 is a crucial component of mTOR signaling
that has been overlooked (Pardo and Seckl, 2013). Yet, many studies demonstrate that S6K2 is associated
with human diseases, including non-small-cell lung cancer (Pardo et al., 2006) and late-stage breast cancer
(Karlsson et al., 2015). We determined that there are high mEAK-7 protein levels in the tumors and lymph
nodes of patients with metastatic cancer, that mEAK-7high patients have poor prognoses, and that mEAK-7
is essential for self-renewal and radioresistance. To determine the evolutionary benefit that cancer cells
gain from upregulating mEAK-7, future research should be focused on elucidating the mechanisms allow-
ing tumorigenesis in a broader range of cancers. Likewise, development of mEAK-7 inhibitors may benefit
patients with metastatic cancers that demonstrate aberrant mTOR signaling associated with high levels of
mEAK-7.Limitations of the Study
Here, we report that DNA-PKcs is a binding partner of the mEAK-7-mTOR complex. Some pitfalls of these
studies are that we lack animal models that could recapitulate human disease. As most of our work is to
identify novel binding partners and the detailed mechanism by which they interact, future studies will be204 iScience 17, 190–207, July 26, 2019
required to examine the role of mEAK-7 in vivo. Also, our inhibitor studies against DNA-PKcs, although
severalfold more specific to DNA-PKcs versus mTOR, could yield some off-target effects and DNA-PKcs
knockout cell lines may not recapitulate all of physiology, suggesting that genetic approaches in vivo
are required to understand the role of DNA-PKcs binding to mTOR to form mTORC3. Thus the role of
this alternative complex to canonical mTOR signaling requires further study in animal models where
mTOR signaling is required for eukaryotic development and disease progression.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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TRANSPARENT METHODS 23 
 24 
Cell lines 25 
H1299 and H1975 are non-small cell lung carcinoma cell lines obtained from ATCC. 26 
MDA-MB-231 is a triple negative breast carcinoma cell line obtained from ATCC. DNA-27 
PKcsWT and DNA-PKcs-/- HEK-293T cells were kindly gifted from Dr. Kathryn Meek, a 28 
Professor at Michigan State University. H1299 cells (ATCC® CRL-5803™) were derived 29 
from a 43 year old male, Caucasian. H1975 cells (ATCC® CRL-5908™) were derived 30 
from an unknown aged, female. MDA-MB-231 (ATCC® HTB-26™) cells were derived 31 
from a 51 year old female Caucasian. HEK-293T cells (ATCC® ACS-4500™) were 32 
derived from an unknown aged, human embryonic kidney tissue. All cell lines are of 33 
human origin. 34 
 35 
Statement of regulatory oversight and approval 36 
The University of Michigan Institutional Review Boards is the committee approving the 37 
cell line experiments, approving the use of human samples from US Biomax, and 38 
confirming that all experiments conform to the relevant regulatory standards. It is not 39 
clear to what extent that sex, gender, and age affected data presented in human tissue 40 
microarrays obtained from US Biomax. The influence or association between these 41 
characteristics would require further assessment, with regards to the conclusions of this 42 
manuscript. Detailed information regarding patient samples from US Biomax can be 43 
accessed in Table S2. 44 
 45 
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Cell culture 46 
Cell culture: Cell lines were grown in Dulbecco’s minimal essential medium (DMEM, 47 
Thermo Fisher Scientific (TFS): cat# 11995-073), without antibiotics/antimycotics and 48 
supplemented with a concentration of 10% fetal bovine serum (FBS, TFS: cat# 10437-49 
036, Lot # 1399413) at 37°C in 5.0% CO2 incubator. Cells were grown in Falcon™ 50 
Tissue Culture Treated Flasks T-75 (Fisher Scientific (FS): cat# 13-680-65) until 75% 51 
confluent and split with Trypsin-EDTA 0.25% (TFS: cat# 25200-056) for 5 min in the 52 
37°C cell incubator. Cells were washed 1x with PBS and resuspended in 10% FBS 53 
containing DMEM. Cells were counted with the LUNA™ Automated Cell Counter (Logos 54 
Biosystems (LB): cat# L10001) utilizing LUNA™ Cell Counting Slides (LB: cat# L12003) 55 
and AO-PI dye (LB: cat# F23001). 56 
 57 
Small interfering RNA or plasmid transfection 58 
Cells were seeded at a density of 500,000 cells per 60 mm TCP and grown for 24 59 
hours. For siRNA transfection, Lipofectamine® RNAiMAX Transfection Reagent (TFS: 60 
cat# 13778-150) was incubated with Opti-MEM® I Reduced Serum Medium (TFS: cat# 61 
31985-070) and 100 nM siRNA was incorporated before introduction to cells at 100 nM 62 
concentration. For plasmid transfection, FuGENE® 6 Transfection Reagent (Promega: 63 
cat# E2691) was incubated with Opti-MEM I Reduced Serum Medium and 2 μg 64 
plasmids were incorporated before introduction into cells. For dual transfection, we 65 
added both solutions. siRNAs used were as follows: mEAK-7 #1 siRNA (TFS: ID# 66 
s33640). mEAK-7 #2 siRNA (TFS: ID# HSS126697). S6K1 #1 siRNA (TFS: ID# 67 
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s12282). S6K1 #2 siRNA (TFS: ID# s12283). S6K2 #1 siRNA (TFS: ID # s12287). S6K2 68 
#2 siRNA (TFS: ID # s12286). Control siRNA (TFS: cat# 4390843). Plasmids were 69 
purchased from Addgene. HA-S6K2 plasmid: pcDNA3-S6K2-WT was a gift from John 70 
Blenis (Addgene plasmid # 17729).  71 
 72 
X-ray irradiation protocol 73 
After appropriate treatment of cells with siRNA, plasmids, chemical compounds, 74 
nutrients, etc, we subjected the cells to X-ray irradiation. The machine is a Polaris IC-75 
320 SC-500 series 2 from Kimtron.  The dose rate is set at 4.5223Gy/min.  X-ray 76 
irradiation of cells was done via the 1.5mm Aluminum filter, with a cone which has a 77 
20x20cm beam pattern and a 50 cm FSD (radiation distance). X-ray irradiation applied 78 
is either 10 gy or 20 gy. 79 
 80 
Immunofluorescence 81 
Deparaffinization and rehydration steps were as follows: xylene for 10 minutes, 100% 82 
ethanol for 5 minutes , 95% ethanol for 5 minutes, 70% ethanol for 5 minutes, Milli Q 83 
water for 10 minutes, and 1x PBST for 10 minutes. Antigen retrieval steps were as 84 
follows: slides were placed in the slide holder to pressure cooker immersed in 10 mM 85 
citric acid (pH 6.0). Then, slides were placed in the microwave and cooked at full power 86 
for 12.5 minutes, finishing when pressure valve has been up for 1 min. Pressurized 87 
steam was exhausted from the pressure cooker. The pressure cooker and slides were 88 
cooled under running water for 15 minutes. Slides were washed with 1x PBS for 10 89 
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minutes. Slides were permeabilized for 10 minutes with 1x PBS with 0.4%Triton-X. 90 
Slides were blocked with 2.5% bovine serum albumin and 1% Tween20 in 1x TBS. 91 
Slides were incubated overnight at 4˚C with primary antibody. Next, slides were washed 92 
with PBS and incubated in secondary antibodies for 1 hour at room temperature. Slides 93 
were washed with PBS with DAPI for 10 minutes. Prolong Gold Antifade with DAPI was 94 
used to mount slides (Fisher cat# P36935). Nikon Ti Eclipse Confocal Microscope (60x 95 
with oil magnification) was used to capture images. Images were captured with or 96 
without 3x digital zoom, 1/32 frames per second, 1024x1024 image capture, 1.2 Airy 97 
Units, 2x line averaging, appropriate voltage and power settings optimized per antibody. 98 
No image modification was performed, except image sizing reduction for figure 99 
preparation. Quantitative analyses were completed via Nikon Analysis Software, with 100 
the data analysis and images representing the average of 3 fields of view and more 101 
than 50% of the tissue core. NSCLC tissue microarray used for protein level detection of 102 
mEAK-7 and p-S6 was purchased from US Biomax (cat# HLug-Squ090Lym-01). 103 
Healthy lymph tissue microarray used for protein level detection of mEAK-7 and p-S6 104 
was purchased from US Biomax (cat# LN802A). NSCLC tissue microarray used for 105 
patient survival was purchased from US Biomax (cat# HLug-Squ150Sur-02). Primary 106 
antibodies for immunofluorescence were as follows: mEAK-7 (Santa Cruz 107 
Biotechnology (SCB) cat# sc-247321) and (Ser240/244) p-S6 ribosomal protein (D68F8) 108 
XP® (Cell Signaling Technologies (CST): cat#5364S). All antibodies were used at 109 
1:1,000 with a working volume of 1.5 mL in 5% BSA in PBS, unless noted otherwise. 110 
Secondary antibodies for immunofluorescence were as follows: Donkey anti-Goat IgG 111 
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Alexa Fluor® 647 (TFS: cat# A-21447), Anti-rabbit IgG (H+L), and F(ab')2 Fragment 112 
Alexa Fluor® 488 Conjugate (CST: cat# 4412S). All antibodies were used at a 113 
concentration of 1:1,000, with a working volume of 1.5 mL in 5% BSA in PBS. DAPI 114 
stain was used for DNA staining. 115 
 116 
Immunoblot analysis 117 
Cells were lysed in cold NP40 lysis buffer (50 mM Tris, 150 mM NaCl, and 1.0% NP-40 118 
at pH 8.0). 50 μg of protein lysate was separated with Novex® Tris-Glycine SDS 119 
Running Buffer 10X (TFS: cat# LC2675-4) and Novex™ WedgeWell™ 4-20% Tris-120 
Glycine Gels (TFS; cat# XP04205BOX), NuPAGE™ 3-8% Tris-Acetate Protein Gels 121 
(TFS; cat# EA03785BOX). Proteins were transferred to PVDF membranes. 4-20% gels 122 
were used for proteins 100 kDa and below, while 3-8% gels were used for proteins 100 123 
kDa and above. Primary antibodies were incubated with membranes overnight at 4°C, 124 
and secondary antibodies were incubated with membranes at room temperature for 1 125 
hour. Membranes were incubated with SuperSignal™ West Pico Chemiluminescent 126 
Substrate (TFS; cat# 34078) or Femto (TFS; cat# 34095) for film capture on HyBlot CL 127 
autoradiography film (Denville Scientific: cat# e3018). Primary antibodies were as 128 
follows: α-mEAK-7 (KIAA1609) mouse monoclonal antibody clone OTI12B1 (formerly 129 
12B1) was obtained from Origene Technologies (OT; cat# TA501037, lot A01). All 130 
antibodies from Cell Signaling Technologies (CST) are rabbit: α-glyceraldehyde-3-131 
phosphate dehydrogenase (CST: cat# 2118S), α-tubulin (CST: cat# 2144S), α-132 
phospho-S6 ribosomal protein (Ser240/244) (CST: cat# 2215S), α-phospho-S6 ribosomal 133 
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protein (Ser235/236) (CST: cat# 2211S), α-S6 ribosomal protein (CST: cat# 2217S), α-134 
phospho-p70 S6 kinase (Thr389) (CST: cat# 9234S), α-S6K1 (CST: cat# 2708S), α-135 
S6K2 (CST: cat# 14130S), α-mTOR (CST: cat# 2983S), α-HA-tag mouse (CST: cat# 136 
2367S), α-HA-tag rabbit (CST: cat# 3724S), α-(Ser65) p-4E-BP1 (CST: cat# 9451S), α-137 
(Thr37/46) p-4E-BP1 (CST: cat# 9459S), α-(Thr70) p-4E-BP1 (CST: cat# 13396S), α-4E-138 
BP1 (CST: cat# 9452S), α-N-cadherin (CST: cat# 13116S), α-noxa (CST: cat# 139 
14766S), α-Cleaved PARP (CST: 5625S), α-(Thr68) p-Chk2 (CST: cat# 2197S), α-Chk2 140 
(CST: cat# 3440S), α-(Ser2448) p-mTOR (CST: cat# 2971S). Concentration of 141 
antibodies: p-S6, S6, and 4E-BP1 used at 1:3,000 dilution and remainder at 1:1,000 142 
dilution in 5% BSA in 1X TBST buffer with 0.04% sodium azide. Secondary antibodies 143 
for immunoblot analysis: 1:4,000 dilution for α-mouse IgG (Promega; cat# W4021). 144 
1:7,500 dilution for α-rabbit (Promega; cat# W4011), and 1:2,000 dilution for α-rabbit 145 
light chain specific antibody (Abcam: cat# ab99697) only for S6K2 IP experiments.  146 
 147 
Chemical Inhibitors 148 
All chemical were resuspended in DMSO, according to manufacturer recommendations. 149 
Rapamycin (CST; cat# 9904S), LY293002 (CST; cat# 9901S), NU7441 (Tocris 150 
Biotechne; cat# 3712). All inhibitors were applied to cells for at least 2 hours, unless 151 
stated otherwise in the manuscript. 152 
 153 
Immunoprecipitation (IP) analysis and mass spectrometry 154 
 Submitted Manuscript: Confidential – iScience May 15, 2019 
  
 8 
After siRNA and/or plasmid transfection, cells were harvested in 1% NP40 lysis buffer or 155 
CHAPS lysis buffer (FIVEphoton Biochemicals (FB): cat# CIB-1) supplemented with 156 
protease inhibitors (FB: cat# PI-1) and phosphatase inhibitors (FB: cat# PIC1). For 157 
antibody-bead conjugation, 1 to 2 μg of antibodies and 50 μL of mixed Protein A/G 158 
PLUS-Agarose (SCB; Cat # sc-2003) were incubated for 1 hour on vertical shaker at 159 
4°C. Afterwards, the antibody-bead mix was washed 3 times with 1x PBS. Next, 250 μg 160 
of protein in CHAPS buffer were incubated with the antibody-bead mix for 1.5 hours on 161 
vertical shaker at 4°C. After incubation, the antibody-bead conjugates were washed 3 162 
times with 1x PBS. Beads were washed 3 times with 1x PBS, and 3x loading buffer with 163 
SDS was added to the bead mix, boiled, spun down, and utilized for immunoblot 164 
analysis. Immunoprecipitation-mass spectrometry: Samples were processed by the 165 
University of Michigan Proteomics core for IP/MS analysis and protocols can be found 166 
on their webpage. Samples submitted to the core were pooled from 3x reactions of HA-167 
mEAK-7 in H1299 cells, as described above. Full excel sheet supplied as Table S1. 168 
Antibodies used for immunoprecipitation reactions were as follows: Anti-HA epitope tag 169 
polyclonal goat IgG Antibody (Novus Biologicals: cat# NB600-362), polyclonal goat IgG 170 
antibody (SCB: cat# sc-2028), α-S6K2 (CST: cat# 14130S), α-mTOR (CST: cat# 171 
2983S), mEAK-7 (SCB, cat# sc-247321). 172 
 173 
Cell Invasion assay 174 
After siRNA transfection and X-ray irradiation, cells were trypsinized and 50,000 cells 175 
were seeded onto Corning® Matrigel® Invasion Chamber 24-Well Plate 8.0 Micron 176 
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(Corning: cat# 354480), with 1 mL of DMEM-AAs without FBS within the top chamber, 177 
and 1 mL of 10% FBS-containing DMEM medium on the bottom of the plate. After 24 178 
hours, we processed the samples with Hema 3™Stat Pack (Fisher: cat# 123-869), 179 
according to manufacturer specifications. Images were captured with a stereoscope, 180 
attached to a digital camera. Brightness and contrast were adjusted, as needed. 181 
Analysis was conducted via student’s t-test. % invasion was counted on 6 individual 182 
experiments per condition as: # cells adhered to the bottom chamber divided by # cells 183 
seeded total.   184 
 185 
Comet Assay 186 
Lysis Buffer, Alkaline Solution, and Eletrophoresis Running Solution were prepared 187 
according to manufacturer’s instructions. Solutions were stored at 4°C. Oxiselect Comet 188 
Agarose (Cell Bio Labs (CBL): #235002) was heated to 95°C for 20 minutes, then 189 
placed in 37°C water bath until use. Cells were grown according to experimental 190 
procedures for siRNA treatment. Two days post siRNA treatment, cells were subjected 191 
to no treatment, 2 gy, and 6 gy X-ray irradiation. Cells were trypsinized and 192 
resuspended at a concentration of 1x105 cells/mL in cold PBS. Then, 10 μL of cell 193 
suspension was mixed with 90 μL of comet agarose. After mixing thoroughly, 75 μL of 194 
this mixture was transferred to the OxiSelect Comet Slide (CBL: #STA-352). Slides 195 
were placed in the dark at 4°C for 15 minutes. Slides were transferred to a small basin 196 
containing pre-chilled Lysis buffer and placed at 4°C for 60 minutes in the dark. Lysis 197 
solution was aspirated from the basin, replaced with pre-chilled Alkaline solution, and 198 
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placed at 4°C in the dark for 30 minutes. Then, Alkaline solution was aspirated and 199 
replaced with pre-chilled TBE Electrophoresis solution. After 5 minutes, TBE 200 
Electrophoresis solution was aspirated and replaced with new TBE Electrophoresis 201 
solution. Slides were transferred to a horizontal electrophoresis chamber and the well 202 
was filled with enough TBE Electrophoresis solution to fully cover the slides. Voltage 203 
was applied for 45 minutes at 20 volts. After electrophoresis, slides were transferred to 204 
a small basin containing pre-chilled DI H2O, and the slides were fully immersed. After 2 205 
minutes, the DI H2O was aspirated and replaced. This rinse was repeated twice. After 206 
the third rinse, slides were immersed in cold 70% ethanol for 5 minutes, then removed 207 
from the basin and allowed to air dry. Once the agarose was dried fully, 100 μL of 208 
diluted Vista Green DNA dye (CBL: cat# 235003, diluted 1:10,000 in TE buffer) was 209 
added to each well and allowed to incubate at room temperature for 15 minutes. Slides 210 
were imaged with Nikon Ti Eclipse Confocal Microscope at 10x magnification lens to 211 
capture images. Images were captured at 1/8 frames per second, 1024x1024 image 212 
capture, 1.2 Airy Units, 2x line averaging, appropriate voltage and power settings for 213 
FITC (488 nm). No image modification was performed, except image sizing reduction 214 
for figure preparation. 215 
 216 
Cancer Stem Cell sorting 217 
Cells were trypsinized and resuspended in DMEM medium with 10% FBS and counted 218 
on Luna cell counter (Logos Biosystems (LB): cat# L10001) using Acridine 219 
Orange/Propidium Iodide dye (LB: cat# F23001) for viability. 1x107 cells were filtered 220 
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into each of 5 labeled 50 mL falcon tubes, through a 40 μm filter. 1x107 cells were 221 
filtered into each of 5 labeled 5 mL round bottom tubes (Falcon: cat# 352235) to be 222 
used as single-color controls. Tubes were centrifuged at 1,000 rpm for 4 minutes at 4°C 223 
and supernatant was discarded. One 5 mL single color control tube was resuspended 224 
with 200 µL PBS with 10% FBS to be used as a negative control. Three of the other 225 
single-color control tubes were resuspended with 200 μL PBS with 10% FBS, and 226 
single color dyes were added as detailed: 2 μL DAPI (Thermo Fisher: cat# D1306), 25 227 
μL CD90 (Biolegend: cat# 328107), and 10 μL CD44 (BD Biosciences: cat# 559942). 228 
The final single-color tube was used for Isotype control. This pellet was resuspended 229 
with 191 μL PBS with 10% FBS and 2 μL DAPI, 2 μL APC Isotype (BD Biosciences: 230 
cat# 340442), and 5 μL FITC Isotype (BD Bioscience: cat# 555909) were added. Cells 231 
in the 50 mL tubes were resuspended with 10 mL PBS with 10% FBS. The stain master 232 
mix was added to each tube to be sorted. Tubes were placed on a rack and incubated 233 
at 37°C for 30 minutes. Cells were rinsed with 1x PBS and resuspended 1x PBS 234 
containing 3% FBS.  Place all tubes on ice until samples will be run on Flow Cytometer 235 
(Sony: Cat# SH800).  236 
 237 
Clonogenicity Assay 238 
Cells were grown according to experimental procedures for siRNA treatment. 239 
Two days post siRNA treatment, cells were subjected to no treatment, 2 gy, and 6 gy X-240 
ray irradiation. 10,000 H1975 cells or 2,500 H1299 cells were plated into 60 mm dishes 241 
with 2 mL DMEM with 10% FBS. Cells were cultured in the incubator for 10 days (until 242 
 Submitted Manuscript: Confidential – iScience May 15, 2019 
  
 12 
control colonies contained >50 cells), and new media and new siRNA were added every 243 
4 days. Cells were fixed with 2 mL of fixation mix (glacial acetic acid (Sigma-Aldrich 244 
537020) and methanol (Sigma-Aldrich 67-56-1), at a 1:7 ratio) for 2-3 minutes at room 245 
temperature and incubated with 2 mL Crystal Violet (Sigma-Aldrich C6158-50G, diluted 246 
to 0.5% in Milli-Q water) for 2 hours at room temperature. After 2 hours, the Crystal 247 
Violet was removed and the dishes were rinsed with 2 mL of media (no FBS added), 248 
pipetting vigorously to dislodge cells. Dishes were rinsed carefully in DI water and 249 
placed on paper towel to dry for 2-3 days. Once plates were dry, colonies were counted 250 
and recorded.  251 
 252 
Spheroid Formation Assay 253 
Cells were grown according to normal experimental procedures for siRNA treatment 254 
(n=6). Two days post siRNA treatment, cells were subjected to no treatment, 2 gy and 6 255 
gy X-ray irradiation. 10,000 H1975 cells or 5,000 H1299 cells were plated into ultralow 256 
attachment plates (Costar: cat# 3471). 2 mL of Serum Free Medium (435 mL MEBM 257 
Medium (Lonza: cat# CC-3151), 10 mL B27 (Gibco: cat# 17504-044), 5 mL Pen/Strep 258 
(Gibco: cat# 15070), 5 mL Lipid Concentrate (Gibco: cat# 11905-031), 2.5 mL Insulin 259 
(Sigma-Aldrich: cat# I6634), 10 μg EGF (BD Biosciences: cat# 354052), 10 μg bFGF 260 
(BD Bioscience: cat# 354060), 500 μg Hydrocortisone (Sigma-Aldrich: cat# H4001), 500 261 
μL 100 mM ß-mercaptoethanol (Sigma-Aldrich: cat# M3148), 2 mg Cholesterol (Sigma-262 
Aldrich: cat# C4951)) were added to each well. Cells were grown for 2 weeks, adding 263 
500 μL of Serum Free Medium every 4 days to ensure cells have adequate nutrients. 264 
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After 2 weeks, the number of spheres growing in each well (spheres must have defined, 265 
circular edges and be made of at least 10 cells) was counted, and representative 266 
images of spheres from each treatment group were taken. 267 
 268 
Statistical analysis and reproducibility  269 
GTEx data acquisition, processing, and statistical analysis information can be found on 270 
“gtexportal.org”. cBioportal was accessed by searching for “MEAK7” or “MEAK7: gain 271 
amp”. Patient derived data from Oncomine were analyzed via unpaired student’s t-test. 272 
Patient derived tissue microarray data were analyzed via paired Mann-Whitney’s U-test. 273 
2D/3D clonogenicity assay, comet assay, cell proliferation, cell migration, and cell size 274 
were analyzed via paired student’s t-test. Immunoblot and immunoprecipitation assays 275 
were repeated at least thrice in all cell lines. 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
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Figure S1, related to Figure 1. MEAK7 is expressed at basal levels in many normal 288 
human tissues, but significantly overexpressed in human cancer patients with 289 
mortality. (A) BioGPS analysis of MEAK7 in human tissues and cells. (B, C) Oncomine 290 
analysis of MEAK7 gene expression of patients with (b) ductal breast carcinoma 291 
(P=2.72x10-6, Fold Change: 2.136) and (c) acute myeloid leukemia (P=7.99x10-6, Fold 292 
Change: 2.655). 293 
 294 
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 296 
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 300 
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 308 
 309 
 Submitted Manuscript: Confidential – iScience May 15, 2019 
  
 16 
 310 
B
A
C
mEAK-7
(Ser70) p-4E-BP1
CD
44-
/CD
90-
CD
44+
/CD
90+
4E-BP1
GAPDH
S6K2
S6K1
n-cadherin
H1975:
H1975
(Thr37/46) p-4E-BP1
D
siR
NA
 co
nt
ro
l
siR
NA
 m
EA
K-
7
0 2 6 0 2 6
siR
NA
 co
nt
ro
l
siR
NA
 m
EA
K-
7
10,000 seeded 25,000 seeded
H1299
H1975
(X-ray irradiation dose gy)
50 kDa
37 kDa
60 kDa
65 kDa
17 kDa
17 kDa
140 kDa
17 kDa
26 kDa(Ser240/244) p-S6
 Submitted Manuscript: Confidential – iScience May 15, 2019 
  
 17 
Figure S2, related to Figure 2 and Figure 3. Normal lymph tissue analysis, H1975 311 
cancer stem cell analysis, and differential cell density clongenicity assay. (A) 6 312 
representative sections of US Biomax tissue microarray LN802a was analyzed using 313 
the antibodies against mEAK-7 and p-S6. (B) Flow sort diagram depicting the 314 
CD44+/CD90+ cell population in H1975 cells. (C) Immunoblot analysis of CD44-/CD90- 315 
and CD44+/CD90+ H1975 cells for mEAK-7 and mTOR signaling. (D) H1299 and 316 
H1975 cells were treated with control or mEAK-7 siRNA, X-irradiated at 2 or 6 gy, and 317 
10,000 or 25,000 cells were seeded into 60 mm TCPs and grown for 10 days. White 318 
bars denote 2.5 mm. This experiment was repeated at least 6 times. 319 
 320 
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 325 
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 328 
 329 
 330 
 331 
 332 
 Submitted Manuscript: Confidential – iScience May 15, 2019 
  
 18 
 333 
Figure S3, related to Figure 3 and Figure 4. Colony formation assay with second 334 
mEAK-7 siRNA, spheroid formation assay with differential cell density or second 335 
mEAK-7 siRNA, and mEAK-7 effect of Noxa expression by X-ray irradiation in 336 
H1299 cells. (A) H1299 cells were treated with control or mEAK-7 siRNA (ID: 337 
HSS126697) for 48 hours, and 500 cells were seeded into 60 mm TCPs and grown for 338 
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10 days. Quantification of colony formation and analysis via student’s t-test (n=6) of (A), 339 
*P<0.01. (B) H1975 cells were treated with control or mEAK-7 siRNA (ID: HSS126697) 340 
for 48 hours, and 500 cells were seeded into 60 mm TCPs and grown for 10 days. 341 
Quantification of colony formation and analysis via student’s t-test (n=6) of (B), *P<0.01, 342 
**P<0.001. (C) H1975 cells were treated with control or mEAK-7 siRNA, subjectd to no 343 
treatment, 2 gy, or 6 gy of X-ray irradiation, and 5,000 cells were seeded into 60 mm 344 
ultra-low attachment plates and grown for 10 days. Quantification of spheroid formation 345 
and analysis via student’s t-test (n=6), *P<0.01, **P<0.001. (D) H1299 cells were 346 
treated with control or mEAK-7 siRNA (ID: HSS126697), and 2,500 cells were seeded 347 
into 60 mm ultra-low attachment plates and grown for 10 days. Quantification of 348 
spheroid formation and analysis via student’s t-test (n=6) of (D), *P<0.01, **P<0.001, 349 
***P<0.0001, ‡P<0.00001, §P<0.000001. (E) H1975 cells were treated with control or 350 
mEAK-7 siRNA (ID: HSS126697), and 5,000 cells were seeded into 60 mm ultra-low 351 
attachment plates and grown for 10 days. Quantification of spheroid formation and 352 
analysis via student’s t-test (n=6) of (E), *P<0.01, **P<0.001, ***P<0.0001, ‡P<0.00001, 353 
§P<0.000001. (F) H1299 cells were treated with control or mEAK-7 siRNA and X-ray 354 
irradiated at 20 gy for 30 minutes, 1 hour, or 2 hours and analyzed for Noxa expression 355 
by DNA damage. 356 
 357 
 358 
 359 
 360 
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 361 
Figure S4, related to Figure 5 and Figure 6. DNA damage mediated S6K1/2 362 
signaling, and DNA-PKcs binding to S6K1, and second mEAK-7 siRNA effect on 363 
DNA damage or nutrient induced S6K2 activation. (A) H1975 cells were treated with 364 
control, 2 unique S6K1, or 2 unique S6K2 siRNAs, then subjected to no treatment, 10 365 
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gy of X-ray irradiation for 30 minutes or 1 hour. Immunoblot analysis on mTOR 366 
signaling. (B) H1299 cells were treated with control, 2 unique S6K1, or 2 unique S6K2 367 
siRNAs, then subjected to no treatment, 10 gy of X-ray irradiation for 30 minutes or 1 368 
hour. Immunoblot analysis on mTOR signaling. (C) HEK-293T DNA-PKcs+/+ or HEK-369 
293T DNA-PKcs-/- cells were transiently transfected with or without pRK7-HA-S6K1-WT, 370 
then untreated or treated with 10 gy of X-ray irradiation for 1 hour. HA-S6K1 was 371 
immunoprecipitated to check DNA-PKcs interaction. This experiment was completed at 372 
least 3 times. (D) HEK-293T DNA-PKcs+/+ or HEK-293T DNA-PKcs-/- cells were 373 
transiently transfected with pcDNA3-HA-S6K2 or pRK7-HA-S6K1-WT for 48 hurs. Next, 374 
cells were starved in DMEM-AAs for 1 hour and reintroduced with 10% FBS in DMEMAAs 375 
for 30 minutes. Cells were collected in CHAPS lysis buffer and immunoprecipitated with 376 
HA antibody. (E) H1975 cells were transiently transfected with pcDNA3-HA-S6K2 and 377 
control or mEAK-7 siRNA (ID: HSS126697) for 48 hours. Next, cells were untreated or 378 
treated with 10 gy of X-ray irradiation for 30 minutes, followed by IP of HA-S6K2, and 379 
probed for activated S6K2 signaling. 380 
 381 
 382 
 383 
 384 
 385 
 386 
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 388 
Figure S5, related to Figure 6. mEAK-7 is required for X-ray irradiation-mediated 389 
mTOR signaling in MDA-MB-231 cells. MDA-MB-231 cells were treated with control 390 
or mEAK-7 siRNA for 48 hours, X-irradiated at 10 gy for 30 minutes, 2 hours, and 8 391 
hours and processed for mTOR signaling. This experiment was completed at least 3 392 
times. 393 
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 404 
Figure S6, related to Figure 6. Dose-dependent analysis of NU7441 on IR-405 
mediated mTOR signaling and inhibition of DNA-PKcs, mTOR, and PI3K 406 
significantly decreased IR-mediated mTOR signaling in H1299 cells. (A) H1299 407 
and H1975 cells were treated with DMSO or 0.5 μM, 1 μM, 5 μM NU7441 for 2 hours 408 
before treated with X-ray irradiation at 10 gy for 30 minutes and 1 hour. Immunoblot 409 
analysis on mTOR signaling. All experiments were repeated at least 3 times. 4E-BP1 410 
was utilized as a loading control. (B) H1299 cells were treated with inhibitors of DNA-411 
PKcs (5 μM NU7441, IC50 = 14 nM), mTOR (100 nM rapamycin, IC50 = 1 nM), and 412 
PI3K (50 μM LY249002, IC50 = 2.3 μM) for 1 hour before treated with X-ray irradiation 413 
at 10 gy for 30 minutes and 1 hour. Immunoblot analysis on mTOR signaling. We 414 
observed that inhibition of DNA-PKCS, mTOR, or PI3K significantly decreased IR-415 
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mediated mTOR signaling. All experiments were repeated at least 3 times. S6 was 416 
utilized as a loading control. 417 
 418 
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Table S1. Immunoprecipitation-mass spectrometry analysis of HA-mEAK-7. 437 
Extended full list of proteins from IP-MS experiment for Figure 5A. 438 
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Table S2: Detailed patient information from US Biomax TMAs. Detailed patient 458 
information regarding TMAs analyzed for Figure 2A-C, Figure 2D, and Figure S2. 459 
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